Protein- and Calcium-Mediated GLP-1 Secretion: A Narrative Review
Open accessThe DOI matches its Crossref record; 149 of the 153 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide 1 (GLP-1) is an incretin hormone produced in the intestine that is secreted in response to nutrient exposure. GLP-1 potentiates glucose-dependent insulin secretion from the pancreatic β cells and promotes satiety. These important actions on glucose metabolism and appetite have led to widespread interest in GLP-1 receptor agonism. Typically, this involves pharmacological GLP-1 mimetics or targeted inhibition of dipeptidyl peptidase-IV, the enzyme responsible for GLP-1 degradation. However, nutritional strategies provide a widely available, cost-effective alternative to pharmacological strategies for enhancing hormone release. Recent advances in nutritional research have implicated the combined ingestion of protein and calcium with enhanced endogenous GLP-1 release, which is likely due to activation of receptors with high affinity and/or sensitivity for amino acids and calcium. Specifically targeting these receptors could enhance gut hormone secretion, thus providing a new therapeutic option. This narrative review provides an overview of the latest research on protein- and calcium-mediated GLP-1 release with an emphasis on human data, and a perspective on potential mechanisms that link potent GLP-1 release to the co-ingestion of protein and calcium. In light of these recent findings, potential future research directions are also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protein also enhances GLP-1, GIP, and insulin secretion, increasing satiety, and delays gastric emptying [32,157,158,161], thereby contributing to weight loss and improved glucose control.”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [32]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Protein also enhances GLP-1, GIP, and insulin secretion, increasing satiety, and delays gastric emptying [32,157,158,161], thereby contributing to weight loss and improved glucose control.”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [32]
The cited source says what the claim attributes to it.
In the citing paper
“This was demonstrated in preclinical and human studies, with protein-calcium co-ingestion producing marked postprandial GLP-1 increases, supporting their potential as adjuncts to GLP-1RA therapy to improve satiety and metabolic regulation [32].”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [32]
In the citing paper
“It enhances glucose-dependent insulin secretion from pancreatic β-cells [32], stimulates somatostatin secretion from δ-cells, which suppresses glucagon secretion from α-cells [31], and exerts cytoprotective effects on β-cells by inhibiting apoptosis, inducing proliferation, and supporting insulin biosynthesis [31,36]”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [32]
In the citing paper
“Protein also enhances GLP-1, GIP, and insulin secretion, increasing satiety, and delays gastric emptying [32,157,158,161], thereby contributing to weight loss and improved glucose control.”
From Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review (2025) · cites this paper as [32]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Epidemiology of Type 2 Diabetes – Global Burden of Disease and Forecasted Trends
Khan, M. A. B., Hashim, M. J., King, J. K., Govender, R. D., Mustafa, H., & Al Kaabi, J. (2019) · Journal of Epidemiology and Global Health · doi:10.2991/jegh.k.191028.001 · Cited by 3,130
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis
Buchwald, H., Estok, R., Fahrbach, K., Banel, D., Jensen, M. D., Pories, W. J., Bantle, J. P., & Sledge, I. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.09.041 · Cited by 2,551
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
Gastrointestinal regulation of food intake
Cummings, D. E., & Overduin, J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30227 · Cited by 1,216
Picot, J., Jones, J., Colquitt, J., Gospodarevskaya, E., Loveman, E., Baxter, L., & Clegg, A. (2009) · Health Technology Assessment · doi:10.3310/hta13410 · Cited by 1,066
Cited by
Li, P., Li, M., Wu, T., Song, Y., Li, Y., Huang, X., Lu, H., & Xu, Z. Z. (2022) · npj Science of Food · doi:10.1038/s41538-022-00158-y · Cited by 45
Nilsson, M. I., Xhuti, D., de Maat, N. M., Hettinga, B. P., & Tarnopolsky, M. A. (2024) · Nutrients · doi:10.3390/nu16244407 · Cited by 43
Beyond Dopamine: Novel Therapeutic Pathways for Parkinson's Disease Through Receptor Signaling
Bhushan, R., Goel, F., & Singh, S. (2025) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273325667241212041540 · Cited by 37
Alsalim, W., Lindgren, O., & Åhrén, B. (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13962 · Cited by 30
Impact of DPP-4 Inhibitors in Patients with Diabetes Mellitus and Heart Failure: An In-Depth Review
Epelde, F. (2024) · Medicina · doi:10.3390/medicina60121986 · Cited by 22
Li, N., Li, C., Li, B., Li, C., Zhao, Q., Huang, Z., Shu, Y., Qu, X., Wang, B., Li, S., et al. (2023) · Nano Letters · doi:10.1021/acs.nanolett.3c03701 · Cited by 20
Proglucagon-derived peptides: human physiology and therapeutic potential
Gasbjerg, L. S., Nielsen, C. K., Suppli, M. P., Grøndahl, M. F. G., Holst, J. J., Knop, F. K., Jeppesen, P. B., & Lund, A. (2025) · Physiological Reviews · doi:10.1152/physrev.00057.2024 · Cited by 22
Heffernan, S., Nunn, L., Harnedy‐Rothwell, P. A., Gite, S., Whooley, J., Giblin, L., Fitzgerald, R. J., & O’Brien, N. M. (2022) · Marine Drugs · doi:10.3390/md20020112 · Cited by 18
“The GLP-1 hormone, which is generated as a result of post translational modifications during proglucagon processing, has received significant attention due to its classification as both an anorexigenic hormone and an incretin hormone [12].”
BackgroundZhuo, Y., Huang, Y., He, J., Hua, L., Xu, S., Li, J., Che, L., Lin, Y., Feng, B., & Wu, D. (2022) · Animals · doi:10.3390/ani12070818 · Cited by 16
“Blood glucose is a primary signal influencing appetite [30], and was unaffected by dietary treatments.”
BackgroundHilkens, L., Praster, F., van Overdam, J., Nyakayiru, J., Singh‐Povel, C. M., Bons, J. A. P., van Loon, L. J. C., & van Dijk, J. (2023) · Journal of Nutrition · doi:10.1016/j.tjnut.2023.12.012 · Cited by 16
Hengist, A., Sciarrillo, C. M., Guo, J., Walter, M. F., & Hall, K. D. (2024) · Obesity · doi:10.1002/oby.24104 · Cited by 13
“Although the LC and LF diets differed by more than just their macro-nutrient composition, it is likely that the differences in gut hormone responses were mainly due to macronutrient differences, as previously reviewed [20, 21].”
Lim, J. J., Liu, Y., Lu, L. W., Sequeira, I. R., & Poppitt, S. D. (2023) · Nutrients · doi:10.3390/nu15102399 · Cited by 11
Novel Metabolites Associated With Blood Pressure After Dietary Interventions
Sun, Y., Zhang, R., Tian, L., Pan, Y., Sun, X., Huang, Z., Fan, J., Chen, J., Zhang, K., Li, S., et al. (2024) · Hypertension · doi:10.1161/hypertensionaha.124.22999 · Cited by 10
“50 Our study provided further evidence that increased GLP-1 secretion can be translated into lower BP. Selenium micronutrient network is also a significant pathway associated with BP after soy and milk protein interventions.”
Zhang, M., Zhu, L., Zhang, H., Wang, X., & Wu, G. (2024) · Food & Function · doi:10.1039/d4fo01290a · Cited by 9
Response of multiple hormones to glucose and arginine challenge in T2DM after gastric bypass
Fanni, G., Katsogiannos, P., Jui, B. N., Sundbom, M., Hetty, S., Pereira, M. J., & Eriksson, J. W. (2022) · Endocrine Connections · doi:10.1530/ec-22-0172 · Cited by 9
“It also has potent secretagogue effects on pancreatic alpha-cells, gut L-cells, and anterior pituitary somatotrope cells (12, 13, 14, 15, 16), but not on ACTH-producing anterior pituitary cells (17).”
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8
“It enhances glucose-dependent insulin secretion from pancreatic β -cells [32], stimulates somatostatin secretion from δ -cells, which suppresses glucagon secretion from α -cells [31], and exerts cytoprotective effects on β -cells by inhibiting apoptosis, inducing proliferation, and supporting…”
GLP-1 and IL-6 regulates obesity in the gut and brain
Yang, K., Wu, Y., He, Y., Dai, J.-X., Luo, Y.-L., Xie, J.-H., & Ding, W. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.123339 · Cited by 8
Wang, J., Liu, L., Liu, H., Qian, Y., Zhang, S., Zheng, S., Jiang, H., Zhou, Y., Cheng, X., Fu, Q., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102327 · Cited by 5
Incretins and Development of Incretin‐based Therapeutics
Zheng, N., Su, X., Zhang, S., & Shen, W. (2025) · Peptide Science · doi:10.1002/9781119824701.ch09 · Cited by 6
Discordance between gut-derived appetite hormones and energy intake in humansPreprint
Hengist, A., Sciarrillo, C. M., Guo, J., Walter, M. F., & Hall, K. D. (2023) · medRxiv · doi:10.1101/2023.05.10.23289718 · Cited by 6
“The propensity for specific nutrients or foods to alter endogenous gut 74 hormone concentrations has been reviewed previously [19, 20].”
BackgroundSlater, T., Mode, W. J. A., Bonnard, L. C., Sweeney, C., Funnell, M. P., Smith, H., Hough, J., James, R. M., Varley, I., Sale, C., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae237 · Cited by 4
Al-Bayyari, N. S., Alhameedy, M., Omoush, R. M., & Ghazzawi, H. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100212 · Cited by 4
“Specific amino acids like glutamine, phenylalanine, arginine, and tryptophan have also been identified as potent stimulators of GLP-1 secretion [49].”
Chen, Y., Lu, S., Li, C., Li, Y., Qin, C., He, Y., Niu, Y., & Sun, Q. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1814249 · Cited by 4
Yang, W., Hao, C., Wang, N., Xie, J., Zhou, B., Yang, Z., Zheng, A., Wei, J., Li, C., Xie, C., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2661854 · Cited by 3
Skarmaliorakis, I., Vasilopoulou, A. G., de Piñeres, V. G., Yannakoulia, M., Anastasiou, C. A., & Mantzoros, C. S. (2024) · Clinical Nutrition · doi:10.1016/j.clnu.2024.11.025 · Cited by 2
A synbiotic supplement reduces body fat and increases GLP-1 secretion in a pilot clinical study
Lin, C.-W., Zou, H.-B., Chen, R.-A., Li, C.-S., Lin, C.-Y., & Hsu, C.-C. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107171 · Cited by 2
Zhang, C., Wang, Z. M., Jiang, Z.-J., Kim, H., Liu, C., & Wang, H. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1838267 · Cited by 2
“Enhancing the ability to secrete GLP-1 represents a complementary and potentially more sustainable strategy (Watkins et al., 2021).”
Poole, E. M., Al-Issa, M., Dong, J., Shelp, G. V., Burns, S. E., Monk, J. M., Dyck, D. J., & Cho, C. E. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101389 · Cited by 2
“Another approach is to stimulate the release of endogenous GLP-1 using nutritional interventions [44], which are of interest due to their long-acting property and, in contrast to pharmaceutical agents, have a reduced likelihood of inducing unexpected side effects after absorption.”
Egelandsdal, B., Haug, A., Rehfeld, J. F., Coutinho, S. R., Ricart, L. R., Martens, H. A., Monfort‐Pires, M., & Martins, C. (2025) · Nutrients · doi:10.3390/nu17091581 · Cited by 1
“Moreover, specific amino acids such as phenylalanine, arginine, glutamine, and tryptophan have been identified as key stimulators of GLP-1 release [55].”
IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis
Liu, Y., Li, X., Yang, J., Qie, S., Wang, X., Wang, X., & Zheng, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1643386 · Cited by 1
Chen, W., Wang, S., Xu, Q., Zhang, H., Yang, M., Zhang, L., & Sun, D. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c14630 · Cited by 1
Falahee, B. E., Apovian, C. M., & Istfan, N. W. (2026) · Obesity · doi:10.1002/oby.70294 · Cited by 1
Bowman, P., Patel, K., McDonald, T. J., Holst, J. J., Hartmann, B., Leveridge, M., Shields, B. M., Hammersley, S., Spaull, S. R., Knight, B., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.14071 · Cited by 1
“…in cases and controls after protein/fat and carbohydrate meals (iAUC 0 – 240 min for GIP after protein/fat 2,319 [ - 947 to 3,713] vs 2,841 [1,568 – 5,895] pmol 9 min/L, P = 0.42 and after carbohydrate 4,013 [1,369 – 7,064] vs 3,787 [1,784 – 7,712] pmol 9 min/L, P = 1.00), Figure 1 and Figure S1.”
InfluentialGlucagon-Like Peptide-1: The Role of Calcium in Gut-Glucose Axis
Foamkom, A.-I., Abdelhady, H. G., & Razzaque, M. S. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-04357-3_10 · Cited by 1
Sun, C., Lochnan, H. A., Sorisky, A., Shaw, J., Ramsay, T., Nolan, C. J., Prentki, M., & RABASA-LHORET, R. P. R. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16528
Swierk, K., Podkościelny, D., Machulski, W., Ciarkowska, M., Makulski, J. K., Franczyk, K., Gierasimiuk, M., Gorski, M., Januszkiewicz, A., & Januszkiewicz, W. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4403
Larner, D. S. (2026) · Cureus · doi:10.7759/cureus.110199
“Figure 2 presents a conceptual model intended to guide future research exploring these potential genotype-environment-treatment interactions [38-39].”
Foods as Modulators of GLP-1 Secretion
Ткаченко, Г. М., Kołodziejska, R., Rymuszka, A., Kamiński, P., & Kurhaluk, N. (2026) · Nutrients · doi:10.3390/nu18182995
Sphinganine as a novel stimulator of GLP-1 secretion
Smits, M. M., Drzazga, A. K., Lackman, J. J., Akhlef, M., Trammell, S. A. J., Baattrup, A. M., Nielsen, O. H., Jensen, K. B., Gerdes, V., van de Laar, A., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06877-1
Dede, S. (2025) · Yildiz Technical University - AVESIS
Bose, P., & Singh, B. P. (2026) · Journal of Functional Foods · doi:10.1016/j.jff.2026.107531 · Cited by 1
Metadata
- Authors
- Watkins, J. D., Koumanov, F., & Gonzalez, J. T.
- Affiliations
- University of Bath (GB)
- Corresponding author
- Gonzalez, Javier T
- Venue
- Advances in Nutrition
- Publisher
- Elsevier BV
- Published
- 2021-11
- Volume
- 12
- Issue
- 6
- Pages
- 2540-2552
- ISSN
- 2156-5376 (ISSN-L)
- 2161-8313
- PMC
- PMC8634310
- OpenAlex
- W3174124430
- Cited by
- 40
- References
- 153
- Citations by year
- 2026: 11 · 2025: 11 · 2024: 8 · 2023: 5 · 2022: 5
- FWCI
- 0.69
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Locations
- Advances in Nutrition (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Pure (University of Bath) (publishedVersion, cc-by)
- Funders
- Arla Foods Ingredients
- MRC (MR/P002927/1)
- LucozadeRibena Suntory Ltd
- Kenniscentrum Suiker & Voeding
- PepsiCo
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, GLP-1 secretion, dietary protein, dietary calcium, amino acid receptors, calcium-sensing receptor, gut hormone secretion, incretins, GLP-1 receptor agonists, DPP-4 inhibition, nutritional strategies, glucose-dependent insulin secretion, satiety
- MeSH terms
- Insulin Secretion, Calcium, Diabetes Mellitus, Type 2, Humans, Insulin-Secreting Cells, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.